In less than a year since the last debt financing, click therapeutics, a digital therapy start-up, recently announced that it had obtained a round B financing of US $52 million.
This round of financing is jointly led by new investors h.i.g. biohealth partners and accelmed partners II, with the participation of health catalyst capital, redemption partners and a top biotechnology hedge fund, as well as existing investment institutions Sanofi ventures, K2 healthventures, hikma ventures and ridgetop health.
David benshoof Klein, CEO and co-founder of the company, described this round of financing as an “important milestone” and revealed that this round of funds will be used to accelerate the development and commercialization of click’s internal prescription digital treatment pipeline and improve its platform capacity.
The New York based startup, founded in April 2012, is committed to providing patients with digital prescription treatment solutions through the development and commercialization of software.
Click therapeutics is literally translated into Chinese as “click therapy”. The company name is very vivid and very consistent with the product – patients and doctors interact by clicking on the application on the mobile phone screen, and then use digital therapy to treat diseases.